Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma

Annals of Surgical Oncology

Volumn 21, Issue 8, 2014, Pages 2525-2531

  Jiang, Betty S ^a   Beasley, Georgia M ^a   Speicher, Paul J ^a   Mosca, Paul J ^a   Morse, Michael A ^a   Hanks, Brent ^a   Salama, April ^a   Tyler, Douglas S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DACARBAZINE; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; MELPHALAN; SORAFENIB; TEMOZOLOMIDE; VINBLASTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG USE; FEMALE; FOLLOW UP; HUMAN; IN TRANSIT MELANOMA; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; PROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; CLINICAL TRIAL; DISEASE COURSE; IMMUNOTHERAPY; LIMB; MELANOMA; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84905125878     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3671-0     Document Type: Article

References (33)

1. Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg. 2011;213(2):306-16.
2. Beasley G, Petersen R, Yoo J, et al. Isolated limb infusion for intransit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15(8):2195-205.
3. Turley RS, Raymond AK, Tyler DS. Regional treatment strategies for in-transit melanoma metastasis. Surg Oncol Clin N Am. 2011;20(1):79-103.
4. Sharma K, Beasley G, Turley R, et al. Patterns of recurrence following complete response to regional chemotherapy for intransit melanoma. Ann Surg Oncol. 2012;19(8):2563-71.
5. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
6. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155-64.
7. Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev. 2007;33(5):484-96. (Pubitemid 47333669)
8. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119-27.
9. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-16. (Pubitemid 29318842)
10. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001;19(15):3477-82. (Pubitemid 32730084)
11. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):715-27. (Pubitemid 44453458)
12. Lesterhuis WJ, Salmons J, Nowak AK, et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One. 2013;8(4):e61895.
13. van der Most RG, Robinson BW, Lake RA. Combining immunotherapy with chemotherapy to treat cancer. Discov Med. 2005;5(27):265-70.
14. Balch CM, Gershenwald JE, Soong S-j, et al. 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-206.
15. Aloia Ta GEOM, et al. Predictors of outcome after hyperthermic isolated limb perfusion: Role of tumor response. Arch Surg. 2005;140(11):1115-20.
16. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol. 2007;25(34):5426-34. (Pubitemid 350232219)
17. Joseph RW, Eckel-Passow JE, Sharma R, et al. Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2. J Immunother. 2012;35(9):711-5.
18. Gyorki DE, Yuan J, Mu Z, et al. Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Ann Surg Oncol. 2013;20(9):3106-11.
19. Hanks BA, Holtzhausen A, Evans KS, et al. Type III TGF-beta receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest. 2013;123(9):3925-40.
20. Shetty G, Beasley G, Sparks S, et al. Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion. Ann Surg Oncol. 2013;20(4):1128-35.
21. Donepudi M, Jovasevic VM, Raychaudhuri P, Mokyr MB. Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells. Cancer Immunol Immunother. 2003;52(3):162-70. (Pubitemid 36384716)
22. Olofsson R, Lindberg E, Karlsson-Parra A, Lindner P, Mattsson J, Andersson B. Melan-A specific CD8 + T lymphocytes after hyperthermic isolated limb perfusion: a pilot study in patients with in-transit metastases of malignant melanoma. Int J Hyperther. 2013;29(3):234-8.
23. Nakayama J, Nakao T, Mashino T, et al. Kinetics of immunological parameters in patients with malignant melanoma treated with hyperthermic isolated limb perfusion. J Dermatol Sci. 1997;15(1):1-8. (Pubitemid 27290641)
24. Speicher PJ, Beasley GM, Jiang B, et al. Hypoxia in melanoma: using optical spectroscopy and EF5 to assess tumor oxygenation before and during regional chemotherapy for melanoma. Ann Surg Oncol. 2013;28:28.
25. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res. 2003;13(5):493-501. (Pubitemid 37266952)
26. Siemann DW, Chapman M, Beikirch A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys. 1991;20(2):287-9.
27. Skarsgard LD, Skwarchuk MW, Vinczan A, Kristl J, Chaplin DJ. The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res. 1995;15(1):219-23.
28. Palazon A, Aragones J, Morales-Kastresana A, de Landazuri MO, Melero I. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. ClinCancer Res. 2012;18(5):1207-13.
29. Dang EV, Barbi J, Yang HY, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell. 2011;146(5):772-84.
30. Gajewski TF, Woo S-R, Zha Y, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013;25(2):268-76.
31. Umansky V, Sevko A. Melanoma-induced immunosuppression and its neutralization. Sem Cancer Biol. 2012;22(4):319-26.
32. Baumgartner JM, Gonzalez R, Lewis KD, et al. Increased survival from stage IV melanoma associated with fewer regulatory T cells. J Surg Res. 2009;154(1):13-20.
33. McCarter M, Baumgartner J, Escobar G, et al. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol. 2007;14(10):2854-60. (Pubitemid 47460650)